Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volrustomig plus chemotherapy in first-line esophageal squamous cell carcinoma
CTR20261713Phase 2Active
- Sponsor
- AstraZeneca
- Start
- May 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of volrustomig in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by AstraZeneca. Started May 2026; status: active.
02
Drugs
volrustomig
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20261713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261713.